澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - piperacillin sodium, quantity: 4.253 g; tazobactam sodium, quantity: 0.547 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - pipertaz sandoz is used to treat serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1) lower respiratory tract infections; 2) urinary tract infections (complicated and uncomplicated); 3) intra-abdominal infections; 4) skin and skin structure infections; 5) bacterial septicaemia; 6) gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, pipertaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in children below the age of 2 years. while pipertaz sandoz (piperacillin/tazobactam) is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibility to pipertaz sandoz (piperacillin/tazobactam). therapy with pipertaz sandoz (piperacillin/tazobactam), however, may be initiated before results of each test are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above, however, once these results are available, appropriate therapy should be continued. in serious infections, presumptive therapy with pipertaz sandoz (piperacillin/tazobactam) may be initiated before susceptibility test results are available. combination therapy with pipertaz sandoz (piperacillin/tazobactam) and aminoglycosides may be used int he treatment of serious infections caused by pseudomonas aeruginosa. both drugs shold be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 100 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topiramate, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - epilepsy: topiramate is indicated in adults and children 2 years and over: - as monotherapy in patients with newly diagnosed epilepsy, - for conversion to monotherapy in patients with epilepsy, and - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome. migraine: topiramate is indicated for the prophylaxis of migraine headache in adults.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glimepiride, quantity: 4 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; povidone; indigo carmine aluminium lake; magnesium stearate - as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with noninsulin dependant diabetes mellitus (type 2 diabetes).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glimepiride, quantity: 3 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; povidone; iron oxide yellow; magnesium stearate - as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with noninsulin dependant diabetes mellitus (type 2 diabetes).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glimepiride, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; povidone; iron oxide yellow; magnesium stearate; indigo carmine aluminium lake - as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with noninsulin dependant diabetes mellitus (type 2 diabetes).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glimepiride, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate; povidone; iron oxide red; magnesium stearate - as an adjunct to diet, exercise and weight loss, to lower the blood glucose in patients with noninsulin dependant diabetes mellitus (type 2 diabetes).

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; silicon dioxide; succinic acid; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - for the short-term treatment of insomnia in adults.